Endologix Inc Gets a Hold Rating from BMO Capital

By Jason Carr

BMO Capital analyst Joanne Wuensch reiterated a Hold rating on Endologix Inc (NASDAQ: ELGX) today and set a price target of $5. The company’s shares opened today at $4.80, close to its 52-week low of $4.21.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 9.3% and a 73.1% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Endologix Inc is Hold and the average price target is $6.42, representing a 33.8% upside.

In a report released today, Stephens also downgraded the stock to Hold with a $6 price target.

The company has a one year high of $14.50 and a one year low of $4.21. Currently, Endologix Inc has an average volume of 1.31M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, VELA Proximal Endograft, Intuitrak Endovascular AAA System, and Nellix Endovascular Aneurysm Sealing System. The company was founded in March 1992 and is headquartered in Irvine, CA.